Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-000456-17-NL
EUCTR2013-000456-17-NL
Active, not recruiting
Phase 1

Plaque at risk (ParisK): Molecular imaging of plaque vulnerability using 18F-choline PET-CT and MRI in carotid artery atherosclerosis patients - ParisK

niversity Hospital Maastricht0 sites25 target enrollmentAugust 12, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPatients with carotid artery stenosis due to atherosclerosis, who are scheduled for carotid endarterectomy or are treated conservatively.MedDRA version: 21.1 Level: PT Classification code 10066537 Term: Atherosclerosis prophylaxis System Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
DrugsFluormethylcholine (18F)

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with carotid artery stenosis due to atherosclerosis, who are scheduled for carotid endarterectomy or are treated conservatively.
Sponsor
niversity Hospital Maastricht
Enrollment
25
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 12, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversity Hospital Maastricht

Eligibility Criteria

Inclusion Criteria

  • •Patients with symptomatic carotid artery stenosis, who are scheduled for carotid endarterectomy or conservative treatment.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 25
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 25

Exclusion Criteria

  • •\-Severe comorbidity, dementia, pregnancy, breast feeding;
  • •\-Serious neurological deficits (hemiparalysis, complete aphasia).
  • •\-Severe heart failure and severe pulmonary dysfunction dependent on oxygen supply;
  • •\-Patients with contra\-indications for MRI

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Plaque at risk (ParisK): Molecular imaging of plaque vulnerability using 18F-choline PET-MRI in patients with carotid artery atherosclerosisarteriosclerosisatherosclerotic plaquecalcification in the vessel wall10003216
NL-OMON47871Medisch Universitair Ziekenhuis Maastricht25
Completed
Not Applicable
Molecular imaging of coronary plaque vulnerability using 18F-fluorocholine PET-MRI in patients with coronary artery disease
NL-OMON47096Medisch Universitair Ziekenhuis Maastricht35
Withdrawn
Not Applicable
sing Molecular Plaque Imaging to Ascertain Cardiovascular Risk in Patients with Sleep ApnoeaAtherosclerotic Cardiovascular DiseaseSleep ApnoeaCardiovascular - Coronary heart diseaseRespiratory - Sleep apnoea
ACTRN12618001327279South Australian Health and Medical Research Institute (SAHMRI)50
Recruiting
Not Applicable
Brain imaging of dementiaPatients with dementia and healthy subjects of the same age group who meet all the criteria.
JPRN-UMIN000046094niversity of Fukui150
Completed
Not Applicable
Investigation of plaque vulnerability: Identification of atherosclerotic plaque angiogenesis using Bevacizumab-800CW and optoacoustic imaging: a single center proof of concept study (CAROTID-OPTOLIGHT)
NL-OMON45786niversitair Medisch Centrum Groningen15